236 related articles for article (PubMed ID: 33684824)
1. Design, synthesis, biological evaluation and structure-activity relationship study of quinazolin-4(3H)-one derivatives as novel USP7 inhibitors.
Li P; Liu Y; Yang H; Liu HM
Eur J Med Chem; 2021 Apr; 216():113291. PubMed ID: 33684824
[TBL] [Abstract][Full Text] [Related]
2. N-benzylpiperidinol derivatives as novel USP7 inhibitors: Structure-activity relationships and X-ray crystallographic studies.
Li M; Liu S; Chen H; Zhou X; Zhou J; Zhou S; Yuan H; Xu QL; Liu J; Cheng K; Sun H; Wang Y; Chen C; Wen X
Eur J Med Chem; 2020 Aug; 199():112279. PubMed ID: 32497973
[TBL] [Abstract][Full Text] [Related]
3. USP7 small-molecule inhibitors interfere with ubiquitin binding.
Kategaya L; Di Lello P; Rougé L; Pastor R; Clark KR; Drummond J; Kleinheinz T; Lin E; Upton JP; Prakash S; Heideker J; McCleland M; Ritorto MS; Alessi DR; Trost M; Bainbridge TW; Kwok MCM; Ma TP; Stiffler Z; Brasher B; Tang Y; Jaishankar P; Hearn BR; Renslo AR; Arkin MR; Cohen F; Yu K; Peale F; Gnad F; Chang MT; Klijn C; Blackwood E; Martin SE; Forrest WF; Ernst JA; Ndubaku C; Wang X; Beresini MH; Tsui V; Schwerdtfeger C; Blake RA; Murray J; Maurer T; Wertz IE
Nature; 2017 Oct; 550(7677):534-538. PubMed ID: 29045385
[TBL] [Abstract][Full Text] [Related]
4. The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status.
Wang M; Zhang Y; Wang T; Zhang J; Zhou Z; Sun Y; Wang S; Shi Y; Luan X; Zhang Y; Wang Y; Wang Y; Zou Z; Kang L; Liu H
Cell Physiol Biochem; 2017; 43(5):1755-1766. PubMed ID: 29049989
[TBL] [Abstract][Full Text] [Related]
5. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth.
Li X; Kong L; Yang Q; Duan A; Ju X; Cai B; Chen L; An T; Li Y
J Biol Chem; 2020 Mar; 295(11):3576-3589. PubMed ID: 32029476
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of USP7 inhibition by selective small-molecule inhibitors.
Turnbull AP; Ioannidis S; Krajewski WW; Pinto-Fernandez A; Heride C; Martin ACL; Tonkin LM; Townsend EC; Buker SM; Lancia DR; Caravella JA; Toms AV; Charlton TM; Lahdenranta J; Wilker E; Follows BC; Evans NJ; Stead L; Alli C; Zarayskiy VV; Talbot AC; Buckmelter AJ; Wang M; McKinnon CL; Saab F; McGouran JF; Century H; Gersch M; Pittman MS; Marshall CG; Raynham TM; Simcox M; Stewart LMD; McLoughlin SB; Escobedo JA; Bair KW; Dinsmore CJ; Hammonds TR; Kim S; Urbé S; Clague MJ; Kessler BM; Komander D
Nature; 2017 Oct; 550(7677):481-486. PubMed ID: 29045389
[TBL] [Abstract][Full Text] [Related]
7. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
[TBL] [Abstract][Full Text] [Related]
8. Characterization of naturally occurring pentacyclic triterpenes as novel inhibitors of deubiquitinating protease USP7 with anticancer activity in vitro.
Jing B; Liu M; Yang L; Cai HY; Chen JB; Li ZX; Kou X; Wu YZ; Qin DJ; Zhou L; Jin J; Lei H; Xu HZ; Wang WW; Wu YL
Acta Pharmacol Sin; 2018 Mar; 39(3):492-498. PubMed ID: 29168472
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of 2-aminopyridine derivatives as USP7 inhibitors.
Xu X; Wang M; Xu H; Liu N; Chen K; Luo C; Chen S; Chen H
Bioorg Chem; 2022 Dec; 129():106128. PubMed ID: 36113266
[TBL] [Abstract][Full Text] [Related]
10. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.
Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA
Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586
[TBL] [Abstract][Full Text] [Related]
11. An Integrated in silico Approach and in vitro Study for the Discovery of Small-Molecule USP7 Inhibitors as Potential Cancer Therapies.
Kanan D; Kanan T; Dogan B; Orhan MD; Avsar T; Durdagi S
ChemMedChem; 2021 Feb; 16(3):555-567. PubMed ID: 33063944
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity.
He Y; Li W; Lv D; Zhang X; Zhang X; Ortiz YT; Budamagunta V; Campisi J; Zheng G; Zhou D
Aging Cell; 2020 Mar; 19(3):e13117. PubMed ID: 32064756
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and molecular docking study of some novel 2,3-disubstituted quinazolin-4(3H)-one derivatives as potent inhibitors of urease.
Akyüz G; Menteşe E; Emirik M; Baltaş N
Bioorg Chem; 2018 Oct; 80():121-128. PubMed ID: 29894891
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition.
Yang H; Li Q; Su M; Luo F; Liu Y; Wang D; Fan Y
Bioorg Med Chem; 2021 Sep; 46():116346. PubMed ID: 34403956
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors.
Chen C; Song J; Wang J; Xu C; Chen C; Gu W; Sun H; Wen X
Bioorg Med Chem Lett; 2017 Feb; 27(4):845-849. PubMed ID: 28108249
[TBL] [Abstract][Full Text] [Related]
16. USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis.
Peng Y; Liu Y; Gao Y; Yuan B; Qi X; Fu Y; Zhu Q; Cao T; Zhang S; Yin L; Li X
J Exp Clin Cancer Res; 2019 Nov; 38(1):468. PubMed ID: 31730000
[TBL] [Abstract][Full Text] [Related]
17. C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site.
Ma J; Martin JD; Xue Y; Lor LA; Kennedy-Wilson KM; Sinnamon RH; Ho TF; Zhang G; Schwartz B; Tummino PJ; Lai Z
Arch Biochem Biophys; 2010 Nov; 503(2):207-12. PubMed ID: 20816748
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Ubiquitin-Specific Protease 7 (USP7) Inhibitors with Novel Scaffold Structures by Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation.
Liu S; Zhou X; Li M; Zhao W; Zhou S; Cheng K; Xu Q; Chen C; Wen X; Sun H; Yuan H
J Chem Inf Model; 2020 Jun; 60(6):3255-3264. PubMed ID: 32282203
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological activation of the p53 pathway by a new compound CYZ2017 exerts anti-tumor effects.
Han Y; Ren Z; Wu Y; Chen Y; Cui Z; Zhu T; Ma M; Du Y; Dong S
Biochem Biophys Res Commun; 2020 Dec; 533(4):1069-1075. PubMed ID: 33012506
[TBL] [Abstract][Full Text] [Related]
20. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Schauer NJ; Liu X; Magin RS; Doherty LM; Chan WC; Ficarro SB; Hu W; Roberts RM; Iacob RE; Stolte B; Giacomelli AO; Perera S; McKay K; Boswell SA; Weisberg EL; Ray A; Chauhan D; Dhe-Paganon S; Anderson KC; Griffin JD; Li J; Hahn WC; Sorger PK; Engen JR; Stegmaier K; Marto JA; Buhrlage SJ
Sci Rep; 2020 Mar; 10(1):5324. PubMed ID: 32210275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
